The constitutive cyclooxygenase (COX)-1 enzyme has been considered the physiologically important isoform for prostaglandin synthesis in the normal kidney. It has, therefore, been suggested that selective inhibitors of the ‘inducible’ isoform (COX-2) may be free from renal adverse effects. We studied the renal effects of the predominantly COX-2 antagonist nabumetone in isolated perfused kidneys. As compared with controls, kidneys removed after in vivo administration of oral nabumetone (15 mg/kg) disclosed altered renal function with reduced glomerular filtration rate, filtration fraction, and urine volume and enhanced hypoxic outer medullary tubular damage. By contrast, renal function and morphology were not affected in vivo by nabumetone or its active metabolite 6-methoxy-2-naphthylacetic acid. The latter agent (10–20 mg/kg i.v.) did not significantly alter renal microcirculation, as opposed to a selective substantial reduction in medullary blood flow noted with the nonselective COX inhibitor indomethacin (5 mg/kg i.v.). In a rat model of acute renal failure, induced by concomitant administration of radiocontrast, nitric oxide synthase, and COX inhibitors, the decline in kidney function and the extent of hypoxic medullary damage with oral nabumetone (80 mg/kg) were comparable to a control group, and significantly less than those induced by indomethacin. In rats subjected to daily oral nabumetone for 3 consecutive weeks, renal function and morphology were preserved as well. Both nabumetone and 6-methoxy-2-naphthylacetic acid reduced renal parenchymal prostaglandin E2 to the same extent as indomethacin. It is concluded that while nabumetone adversely affects renal function and may intensify hypoxic medullary damage ex vivo, rat kidneys are not affected by this agent in vivo, both in acute and chronic studies. COX selectivity may not explain the renal safety of nabumetone.

1.
Tarloff JB: Analgesics and nonsteroidal anti-inflammatory drugs; in Goldstein RS (ed): Comprehensive Toxicology. New York, Pergamon/Elsevier Science, 1997, vol 7, pp 583–600.
2.
Badr KF, Jacobson HR: Arachidonic acid metabolites in the kidney; in Brenner BM, Rector FC (eds): The Kidney, ed 4. Philadelphia, Saunders, 1991, pp 808–814.
3.
Ichihara A, Imig JD, Inscho EW, Navar LG: Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: Interaction with neuronal NOS. Am J Physiol 1998;275:F605–F612.
4.
Parekh N, Zou AP: Role of prostaglandins in renal medullary circulation: Response to different vasoconstrictors. Am J Physiol 1996;271:F653–F658.
5.
Agmon Y, Brezis M: Effects of non-steroidal anti-inflammatory drugs upon intrarenal blood flow: Selective medullary hypoperfusion. Exp Nephrol 1993;1:357–363.
6.
Heyman SN, Fuchs S, Brezis M: The role of medullary ischemia in acute renal failure. New Horizons 1995;3:597–607.
7.
Lear S, Silva P, Kelley VE, Epstein FH: Prostaglandin E2 inhibits oxygen consumption in rabbit medullary thick ascending limb. Am J Physiol 1990;258:F1372–F1378.
8.
Brezis M, Rosen S: Hypoxia of the renal medulla: Its implications for disease. N Engl J Med 1995;332:647–655.
9.
Eriksson LO, Larsson B, Andersson KE: Biochemical characterization and autoradiographic localization of [3H]PGE2 binding sites in rat kidney. Acta Physiol Scand 1990;139:405–415.
10.
Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S: Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1991;40:632–642.
11.
Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein F, Rosen S: Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988;82:401–412.
12.
Brezis M, Heyman SN, Dinour D, Epstein FH, Rosen S: Role of nitric oxide in renal medullary oxygen balance: Studies in isolated and intact rat kidneys. J Clin Invest 1991;88:390–395.
13.
Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M: Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994;94:1069–1075.
14.
Heyman SN, Fuchs S, Yaffe R, Beeri R, Elazarian L, Brezis M, Rosen S: Renal microcirculation and tissue damage during acute ureteral obstruction: The effect of saline infusion, indomethacin and radiocontrast. Kidney Int 1997;51:653–663.
15.
Heyman SN, Rosen S, Fuchs S, Epstein FH, Brezis M: Myoglobinuric acute renal failure in the rat: A role for medullary hypoperfusion, hypoxia and tubular obstruction. J Am Soc Nephrol 1996;7:1066–1074.
16.
Heyman SN, Rosen S, Darmon D, Goldfarb M, Bitz H, Shina A, Brezis M: Endotoxin-induced renal failure. II. A role for tubular hypoxic damage. Exp Nephrol 2000;8:275–282.
17.
Eknoyan G, Quinibi WY, Grissom RT, Tuma SN, Ayus J: Renal papillary necrosis: An update. Medicine (Baltimore) 1982;61:55–73.
18.
Elseviers MM, Waller I, Nenoy D, et al: Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: Results of the ANNE Study. Nephrol Dial Transplant 1995;10:808–814.
19.
Dewitt DL, Meade EA, Smith WL: PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993;95(suppl):40–44.
20.
Massferrer JL, Zweifel BS, Manning PT, Hauser SD, Leaf KM, Smith WG, Isakson PC, Seibert K: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228–3232.
21.
Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P: Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563–582.
22.
Warrington SJ, Ravic M, Dawnay A: Renal and general tolerability of repeated doses of nimesulide in normal subjects. Drugs 1993;46(suppl 1):263–269.
23.
Aronoff GR: Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992;19(suppl 36):25–31.
24.
Freestone S, McAuslane JA, Presscott LF: Effects of tenoxicam on renal function and the disposition of inulin and p-aminohippurate in healthy volunteers and patients with chronic renal failure. Br J Clin Pharmacol 1991;32:495–500.
25.
Steinhauslin F, Munafo A, Buclin T, Macciocchi A, Biollaz J: Renal effects of nimesulide in furosemide-treated subjects. Drugs 1993;46 (suppl 1):257–262.
26.
Whelton A, Stout RL, Spilman PS, Klassen DK: Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: A prospective, randomized, crossover comparison. Ann Intern Med 1990;113:481–482.
27.
Warrington SJ, Lewis Y, Dawnay A, Johnston A, Kovacs IB, Lamb E, Ravic M: Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic miocrosomal oxidation. Postgrad Med J 1990;66 (suppl 4):35–40.
28.
Heintz RC: Tenoxicam and renal function. Drug Saf 1995;12:110–119.
29.
Brooks PM, McCredie M, Prowse M, Podgorski M, Forrest M, Munro I, Boutagy J, Pei-Ling L: Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency. Pharmatherapeutica 1986;4:665–672.
30.
Fusetti G, Magni E, Armandola MC: Tolerability of nimesulide: Epidemiological data. Drugs 1993;46(suppl 1):277–280.
31.
Morgan GJ, Poland M, DeLapp RE: Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993;95(supppl):19–27.
32.
Cook ME, Wallin JDF, Thakur VD, Kadowitz PJ, McNamara DB, Garcia MM, Lipani JA, Poland M: Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997;24:1137–1144.
33.
Ross BD, Epstein FH, Leaf A: Sodium reabsorption in the perfused rat kidney. Am J Physiol 1973;225: 1165–1171.
34.
Ackerman Z, Karmeli F, Amir G, Rachmilewitz D: Renal vasoactive mediator generation in portal hypertensive and bile duct ligated rats. J Hepatol 1996;24:478–486.
35.
Bauminger S, Zor U, Lindner HR: Radioimmunological assay of prostaglandin synthetase activity. Prostaglandins 1973;4:313–324.
36.
Brezis M, Rosen S, Stoff JS, Spokes K, Silva P, Epstein FH: Inhibition of prostaglandin synthesis in rat kidney perfused with and without erythrocytes: Implication for analgesic nephropathy. Miner Electrolyte Metab 1986;12:326–332.
37.
Melarange R, Gentry C, Moore G, Durie M, Blower PR: One month repeat oral dosing of nabumetone, in contrast with diclofenac, does not alter gastrointestinal mucosal integrity in the rat. Arthritis Rheum 1992;35(suppl):342.
38.
Itskovitz HD, Stemper J, Pacholczyzk D, McGiff JC: Renal prostaglandins: Determinants of intrarenal distribution of blood flow in the dog. Clin Sci Mol Med 1973;45(suppl):321–324.
39.
Birck R, Knoll T, Braum C, Van der Woude FJ, Rohmeiss P: Effects of selective cyclooxygenase-2 inhibitor meloxicam on renal hemodynamics compared to indomethacin (abstract). J Am Soc Nephrol 1997;8:344A.
40.
Heyman SN, Karmeli F, Rachmilewitz D, Haj Yehia A, Brezis M: Intrarenal nitric oxide monitoring with a Clark-type electrode: Potential pitfalls. Kidney Int 1997;51:1619–1623.
41.
Heyman SN, Darmon D, Bitz H, Brezis M, Shina A, Rosen S: Selective cyclooxygenase (COX)-2 inhibition adversely affects function and morphology in the isolated perfused rat kidney (abstract). J Am Soc Nephrol 1998;9:595.
42.
Bosch-Marce M, Claria J, Titos E, Masferrer JL, Altuna R, Poo JL, Jimenez W, Arroyo V, Rivera F, Rodes J: Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrrhotic rats. Gastroenterology 1999;116:1167–1175.
43.
Harrison-Bernard LM, Carmines PK: Impact of cyclo-oxygenase blockade on juxtamedullary microvascular response to angiotensin II in the rat kidney. Clin Exp Pharmacol Physiol 1995;22:732–738.
44.
Kocaoglu S, Karan A, Berkan T, Basdemir G, Akpinar R: Urinary gamma-glutamyltransferase activity in rats with nonsteroidal anti-inflammatory drug-induced nephrotoxicity. Arch Immunol Ther Exp (Warsz) 1997;45:7307.
45.
Rossat J, Maillard M, Nussberger J, Drower E, Brunner HR, Burnier M: Acute renal effects of selective inhibition of cyclooxygenase-2 in healthy salt-depleted subjects (abstracts). J Am Soc Nephrol 1998;9:346A.
46.
Whelton A, Schulman G, Verburg KM, Drower EJ, Geis GS: Effects of celecoxib and naproxen on renal function in the elderly (abstract). J Am Soc Nephrol 1999;10:471.
47.
Perazella MA, Eras J: Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937–940.
48.
Braden GL, O’Shea M, Mulhern J, Germain MJ: COX-2 inhibitor acute renal failure: Association with hyperkalemia and type IV renal tubular acidosis (abstract). J Am Soc Nephrol 2000;11:126A.
49.
Kornhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 1997;272:F460–F468.
50.
Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504–2510.
51.
Wang JL, Chen HF, Zhang MZ, McKanna JA, Harris RC: Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998;275:F613–F622.
52.
Abassi Z, Brodsky S, Rubinstein I, Gealekman O, Hoffman A, Winaver J: Intrarenal expression and distribution of cycloxygenase isoforms in rats with experimental heart failure. Am J Physiol 2001;280:F43–F53.
53.
Yang T, Schnermann JB, Briggs JP: Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol 1999;227:F1–F9.
54.
Wang JL, Cheng HF, Harris RC: Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999;34:96–101.
55.
Liu KL, Aissa A, Lareal MC, Benzoni D, Sassard J, Zech P: Basal prostaglandin synthesis by the isolated perfused rat kidney. Prostaglandins Leukot Essent Fatty Acids 1990;39:261–265.
56.
Silva P, Rosen S, Spokes K, Taylor M, Epstein FH: Influence of endogenous prostaglandins on mTAL injury. J Am Soc Nephrol 1990;1:808–814.
57.
Qi Z, Breyer MD: Cyclooxygenase-2 inhibitors reduce renal medullary flow (abstract). J Am Soc Nephrol 2000;11:364A.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.